Skip to main content
. 2018 Jun 8;11:1756284818777945. doi: 10.1177/1756284818777945

Figure 3.

Figure 3.

Effects of plecanatide and placebo on the percentage of durable overall complete spontaneous bowel movement (CSBM) responders and weekly CSBM responders after 12 weeks of drug treatment, and a 2-week drug-free follow-up period.

Effects of plecanatide and placebo on the percentage of durable overall CSBM responders (a) and weekly CSBM responders (b) after 12 weeks of drug treatment, and a 2-week drug-free follow-up period. [Clinical Trials.gov identifier: NCT01982249 SHOULD READ NCT01982240]

All error bars represent 95% confidence intervals; values in 3(b) are least squares mean; *p = 0.001, **p = 0.003, $p = 0.005, p = 0.011 versus placebo.